Replies to post #10397 on The Rising Influence of Rising Affluence

[DewDiligence]

ABT addendum: It’s been 2.5 years since the ABT/ABBV separation and it’s only now that the business of selling branded generics is really beginning to shine. ABT owes a big “thank you” to MYL for buying ABT’s moribund branded-generics business in Europe and other developed markets (in order to do a tax inversion into a Dutch–based company).

Any of the Big Pharma could have done what ABT is doing, but only ABT had the foresight to see that selling branded generics in emerging markets would be not just a decent business, but rather a superb business with a longrunning demographic tailwind.

[DewDiligence]

ABT -7.3%, which is unheard of. Why? Because ABT has large and profitable businesses selling infant formula and branded-generic drugs in China and other emerging markets.

[DewDiligence]

ABT's 3Q15 sales jump 11% in constant currency:

http://finance.yahoo.com/news/abbott-reports-third-quarter-2015-114500954.html

CEO Miles White said, “The slowdown in China does not apply to drugs.”

3Q15 results were adversely affected by the strong US Dollar, but YoY sales growth in constant currency was a robust 11% (excluding the MYL divestiture), the same growth rate as in 2Q15 (#msg-115595349).

ABT tightened 2015 guidance for non-GAAP EPS to $2.14-2.16 (from old range of $2.10-2.10).